Ray Dalio's CRL Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 22,054 shares of Charles River Laboratories International, Inc. (CRL) worth $4.4 M, representing 0.02% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in CRL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 19,908 shares. Largest reduction occurred in Q4 2015, reducing 17,000 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +2,146 | Add 10.78% | 22,054 | $199.48 |
| Q3 2025 | +19,908 | New Buy | 19,908 | $156.46 |
| Q2 2024 | -1,100 | Sold Out | 0 | $0.00 |
| Q1 2024 | -1,665 | Reduce 60.22% | 1,100 | $270.95 |
| Q4 2023 | -240 | Reduce 7.99% | 2,765 | $236.40 |
| Q3 2023 | -1,301 | Reduce 30.21% | 3,005 | $195.98 |
| Q2 2023 | +1,124 | Add 35.32% | 4,306 | $210.25 |
| Q1 2023 | -263 | Reduce 7.63% | 3,182 | $201.82 |
| Q4 2022 | +1,392 | Add 67.80% | 3,445 | $217.90 |
| Q3 2022 | -3,553 | Reduce 63.38% | 2,053 | $196.79 |
| Q2 2022 | +666 | Add 13.48% | 5,606 | $214.06 |
| Q1 2022 | +3,453 | Add 232.21% | 4,940 | $284.01 |
| Q4 2021 | +838 | Add 129.12% | 1,487 | $376.60 |
| Q3 2021 | +649 | New Buy | 649 | $412.94 |
| Q4 2019 | -3,406 | Sold Out | 0 | $0.00 |
| Q3 2019 | +3,406 | New Buy | 3,406 | $132.41 |
| Q1 2019 | -15,166 | Sold Out | 0 | $0.00 |
| Q4 2018 | +12,120 | Add 397.90% | 15,166 | $113.15 |
| Q3 2018 | -7,459 | Reduce 71.00% | 3,046 | $134.60 |
| Q2 2018 | -1,740 | Reduce 14.21% | 10,505 | $112.23 |
| Q1 2018 | +12,245 | New Buy | 12,245 | $106.74 |
| Q4 2017 | -2,574 | Sold Out | 0 | $0.00 |
| Q3 2017 | -4,135 | Reduce 61.63% | 2,574 | $108.00 |
| Q2 2017 | +6,709 | New Buy | 6,709 | $101.21 |
| Q1 2016 | -2,687 | Sold Out | 0 | $0.00 |
| Q4 2015 | -17,000 | Reduce 86.35% | 2,687 | $80.39 |
| Q3 2015 | +19,687 | New Buy | 19,687 | $63.54 |
| Q2 2015 | -4,700 | Sold Out | 0 | $0.00 |
| Q1 2015 | -500 | Reduce 9.62% | 4,700 | $79.36 |
| Q4 2014 | +1,000 | Add 23.81% | 5,200 | $63.65 |
| Q3 2014 | +4,200 | New Buy | 4,200 | $59.76 |
Ray Dalio's Charles River Laboratories International Investment FAQs
Ray Dalio first purchased Charles River Laboratories International, Inc. (CRL) in Q3 2014, acquiring 4,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Charles River Laboratories International, Inc. (CRL) for 31 quarters since Q3 2014.
Ray Dalio's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q3 2025, adding 19,908 shares worth $3.11 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 22,054 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $4.4 M.
As of the Q4 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Charles River Laboratories International, Inc. (CRL) was 22,054 shares, as reported at the end of Q4 2025.